Jamesi Novum

Metformin Hydrochloride and Sitagliptin, the active ingredients in Jamesi Novum, are a biguanide and a DPP‑4 inhibitor presented as an oral tablet for adult use. They treat type 2 diabetes mellitus in patients who need combined glucose‑lowering therapy.

GNH USA supplies Jamesi Novum as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Jamesi Novum is indicated for type 2 diabetes mellitus, a chronic metabolic disorder that impairs glucose regulation.

- Type 2 diabetes mellitus: improves overall glycemic control when used with diet and exercise. - Inadequate control on metformin alone: adds DPP‑4 inhibition to further lower HbA1c. - Adults requiring combined therapy: reduces fasting and post‑prandial glucose levels.

Adverse reactions may occur with any antidiabetic regimen and should be monitored.

Common Side Effects: - Gastrointestinal upset: nausea, abdominal discomfort, or diarrhea. - Headache: mild to moderate intensity. - Mild hypoglycemia: especially when combined with insulin or sulfonylureas.

Serious or Rare Side Effects: - Lactic acidosis: a rare but life‑threatening metabolic complication. - Pancreatitis: severe abdominal pain with elevated enzymes. - Severe allergic reactions: rash, angioedema, or anaphylaxis. - Hepatic dysfunction: elevated liver enzymes or jaundice. - Renal impairment: worsening kidney function may necessitate discontinuation.

Careful assessment and monitoring are required before and during therapy.

- Renal function: evaluate eGFR before initiation and periodically thereafter. - Hepatic function: avoid in patients with severe hepatic impairment. - Lactic acidosis risk: contraindicated in conditions causing hypoxia or severe infection. - Pregnancy and lactation: use only if potential benefit justifies potential risk. - Drug interactions: review concomitant medications for possible additive effects. - Store at ambient temperature: keep in the original container, protect from moisture and heat.

Jamesi Novum may interact with several drug classes; awareness of the interaction level guides clinical decisions.

Major Interactions (Avoid): - Severe renal impairment (eGFR <30 mL/min/1.73 m²): increased metformin accumulation. - Strong CYP3A4 inhibitors (e.g., ketoconazole): raise sitagliptin plasma levels. - Concurrent sulfonylureas or insulin: heightened risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Iodinated contrast agents: temporary discontinuation of metformin may be needed. - Diuretics: may affect renal clearance of metformin. - Beta‑blockers: can mask hypoglycemia symptoms, requiring closer glucose monitoring.